Could Biotech Market Soar with Donald Trump as President in 2017?

After the recent victory of Donald Trump, there is an industry that has everyone abuzz as of late, from entrepreneurs to venture capitalists and investors and it’s been attracting them in droves.
Unless you’ve been hiding under a rock, you know that a lot rides on this movement. Political elections, cultural and societal shifts, medical benefits and financial windfalls all play a part, which is why we’d like to take the time to discuss one of the best, and most nuanced, market opportunities you’ll come across all year.

During the presidential campaign, Donald Trump expressed his point of view on the current market. “Be careful of a bubble because what you’ve seen in the past might be small potatoes compared to what happens,” he said in his campaign announcement speech in June.

Donald Trump’s election to the presidency rocked global markets, sending stocks in the U.S. and abroad plunging as investors fled to safe havens like gold. Despite the initial pullback, there are ways to play the markets under a President Trump.

New market opportunities for the same old problemsIn each state where the issue was on the ballot—Florida, Arkansas, Montana, and North Dakota—voters supported initiatives that would provide or expand patients’ access to cannabinoid products for ailments that include post-traumatic stress disorder, epilepsy, Parkinson’s disease, cancer, and glaucoma.

And last year at a political rally, Trump said, “In terms of marijuana and legalization, I think that should be a state issue, state-by-state,” adding, “I think medical should happen—right? Don’t we agree? I think so.” – []
New market opportunities are rising on the horizon and smart U.S. biotech companies could potentially use the momentum to skyrocket their sales. Prescription painkiller sales are set to increase by 15% and hit $8.4 billion by 2017, due in part to the U.S. Food and Drug Administration’s recent decision to ban any generic versions of OxyContin based on the powerful painkiller’s original formulation, which does not include anti-abuse features designed to make the pill less addictive.

Experts are predicting a race across the pharmaceutical industry to create a market where all opioids have abuse-deterrent properties, according to the Wall Street Journal.

Chronic pain is something that nearly 25 million adult Americans suffer from on a daily basis. Add severe pain to that figure, and now you’re talking upwards of 50 million adults. Many of these tens of millions have no place to turn but to addictive opiates, a last—but only—line of resort for those who are looking to return to some semblance of a normal, functional life. Now think of what it would mean for that opiate market to be totally upended by a powerful but safe alternative. It could saves lives and families.

Pain relief is one of the biggest and broadest ongoing medical challenges of our time, and it’s a problem that’s led to unprecedented opiate addiction. But new science now offers a way out through the use of cannabosides that could replace dangerous opiates for pain relief.

The breakthrough, pioneered by Vitality Biopharma (OTCQB:VBIO), discovered a safe treatment for neurological and inflammatory disorders through a process originally used in the natural sweeteners industry. But as is often the case, an additional purpose was found for this process—a purpose with an even larger market. Vitality soon discovered that it could also use this same process to create an alternative to addictive opiate pain relief—essentially upending the entire $17 billion opiate prescription market.

Could these 2 biotech products beat traditional painkillers?infogr7

Right now, Vitality (OTCQB:VBIO) has three connabinoid-based drugs in the late stages of development. These include:

  • VB100, which treats inflammatory bowel diseases.
  • VB210, which treats the symptoms of multiple sclerosis and addresses fibromyalgia, neuropathic pain and irritable bowel syndrome.
  • The third drug is aimed at treating epilepsy, schizophrenia, Huntington’s Disease and Guillain-Barr Syndrome.

VB100 and VB210 should be ready for clinical trials in 2017. And once the results of those trials come in, Vitality shareholders could see some significant profits.

Better yet, Vitality isn’t resting on its laurels. It has already created more than 40 cannaboside compounds using the proprietary technology described above and it has filed for patent protection on each of them.
Pain relief technology that is safer than prescription painkillersOne of the unique things about Vitality’s new painkillers is that they’re delivered to the body in a pharmacologically inactive form. The body then converts them into their active form during the digestive process. Pharmaceutical compounds that work like this are known as “prodrugs.”

This is important because, in many cases, the pharmacologically active form of the drug often has a long history of clinical investigation and use. In other words, its safety and efficacy has already been demonstrated. This is a large advantage for Vitality because as you’ve seen, its technology alters existing compounds to improve their effectiveness and to reduce their side-effects.

Significant Growth Have Historically Been Found in the Biotech Market130401125714-cnn-money-hot-stocks-image-620xaAccording to CNN Money, 4 out of 5 of the Best Performing IPOs in 2015 have been pharmaceutical and biotech companies including companies such as Spark Therapeutics Inc and Aduro BioTech Inc.


The Winners: Too Late To Invest In, But Good To StudyWe constantly watch the biggest giants of the Biotech sector to source ideas and trends from, and here we can highlight some of the most successful companies:

GW Pharmaceuticals
Market Cap: $3.08B
GW is developing a portfolio of cannabinoid medicines, including Sativex, for the treatment of MS spasticity and cancer pain, and Epidiolex for the treatment of childhood epilepsy. GW’s lead product, Sativex is now approved in 27 countries.


Insys Therapeutics Inc
Market Cap: $801M
Insys Therapeutics has developed a drug called SUBSYS, that is used for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and are tolerant to opioid therapy for their underlying constant cancer pain.


Gilead Sciences, Inc.
Market Cap: $98.2B
Gilead Sciences is a research-based biopharmaceutical company that specializes in the development and commercialization of innovative medicine for unmet medical needs. This includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory illness and for cardiovascular conditions. They can boast being the first to market a complete treatment regimen for HIV that comes as a single once-daily pill, and the first oral antiretroviral pill to reduce the risk of HIV transmission in certain high-risk adults

Take a look at GW Pharmaceuticals PLC (NASDAQ:GWPH) and Insys Therapeutics Inc (NASDAQ:INSY). They may be the market’s top-of-mind names for cannabinoid-based medicines but things are changing. A young and energetic player has stepped into the field and got a whole lot more potent this week. Vitality Biopharma Inc (OTCQB:VBIO) announced it had widened its patent protection of its glycoside prodrug portfolio.

It’s not an simple matter for most investors to wrap their head around. While most know that cannabis-based therapies can have a variety of therapeutic effects, many investors may not appreciate the diversity of cannabinoid-based treatments. One of the distinguishing factors is the difference between drugs and prodrugs. Whereas most of the drugs in development by names like Insys Therapeutics and GW Pharmaceuticals are delivered already in their active form, prodrugs don’t become their active form until after administered. As such, prodrugs allow for a more targeted delivery of a drug, and therefore each dose can do more than it’s competitors.

Demand for Vitality’s Drugs Could Soar Off the ChartsMen and women all over the world are in desperate need of safe, effective, non-addictive pain-relief to replace the opioid painkillers so many rely on now.
While opioid painkillers such as OxyContin, hydrocodone, Vicodin, Codeine and Percocet are usually effective, they are also highly addictive and that has led to an epidemic of drug abuse even among law-abiding citizens who have accidentally become addicted. Worse yet, addiction to prescription painkillers can become a gateway to more serious drugs, including heroin.

Believe it or not, studies show that between 75% to 86% of heroin users started with prescription opioid pain relievers. Some might be inclined to blame the patient, but the shocking truth is that many people get addicted while simply following doctor’s orders exactly.

It’s just that dangerous. Because of that, more than 2.4 million Americans suffer from a severe opioid-use disorder, which includes dependence on heroin or a prescription opiate drug. This has led to more than 47,055 Americans died from a drug overdose in just 2015 alone — more than were killed in car accidents. Opioids were involved in 61% of those overdoses. This has led to a government crackdown on doctors who government officials believe overprescribe prescription opioids, regardless of the risk.

If discovered today, it would be “hailed as a medical breakthrough”infogr4_quote
Perfect Momentum for VitalityVitality’s momentum has been nothing but breathtaking. VBIO mitigates it risk by cultivating strong multiple relationships and assets, varied along a broad spectrum of healthcare sectors. Since multiple assets mature at different times during the development cycle, success is steady and that value is passed on to VBIO shareholders.
Since the financial crisis, the Biotech Index is up by 300%, with 2014 holding out as a record IPO year with continued growth, partnerships and mergers and acquisitions.

The demand for affordable drugs that maintain a high quality is stubborn and like the overall healthcare industry, will only continue to grow. The Medical and Biotech market is growing exponentially and pharmaceutical companies are eagerly expanding their portfolios with innovative companies like VBIO.

People behind this breakthrough technologyVitality Biopharma is managed by an experienced leadership team with a strong track record of success.

The Right Technology for The Biotech Market?Vitality Biopharma (OTCQB: VBIO) is uniquely positioned to propel innovative research in the area of cannabinoid compound use for pain relief. Unlike competitors, they’re taking advantage of exciting new cannabinoid delivery and are truly delivering something new and innovative, something bound to change the medical world forever.
Check Vitality Biopharma Website: here
Disclaimer: This release/advertorial is a commercial advertisement and is for general information purposes only. This is a Native Advertisement, meaning it is an informational paid marketing piece. makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Please review all investment decisions with a licensed investment advisor.
This Advertorial contains forward-looking statements that involve risks and uncertainties. This Advertorial contains or incorporates by reference forward-looking statements, including certain information with respect to plans and strategies of the featured Company. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believe(s)” “anticipate(s)”, “plan(s)” “expect(s)” “project(s)” “will” “make” “told” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cau se actual events or actual results of the Company to differ materially from these indicated by such forward-looking statements. Certain statements contained herein constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business, financing, business trends, future operating revenues and expenses. There can be no assurance that such expectations will prove to be correct. Investors are cautioned that any forward-looking statements made by the Company, or contained in this advertorial are not guarantees of future performance, and that the Issuer’s actual results may differ materially from those set forth in the forward-looking statements. Difference in results can be caused by various factors including, but not limited to, the Company’s ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. To reiterate, information presented in this advertorial contains “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this advertorial may be identified through the use of words such as “expects,” “will,” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating certain actions “may,” “could,” or “might” occur. More information on the Company may be found at; readers can review all public filings by the Company at the SEC’s EDGAR page. is not a certified financial analyst or licensed in the securities industry in any manner. The information in this Advertorial is subjective opinion and may not be complete, accurate or current and was paid for, so this could create a conflict of interest.